A fixed rule set over this filing's XBRL figures and the number of high-severity risks found in it — no model judgement.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Incyte's Q2 FY2026 10-Q filing did not include XBRL income statement, balance sheet, cash flow, or ratio data, so this analysis is based solely on qualitative disclosures from the MD&A and Risk Factors sections, which highlight continued reliance on JAKAFI, pipeline advancement (INCA033989, tafasitamab, latarcibart), and the newly approved JAKAFI XR extended-release formulation.
No financial metrics available for Q2 FY2026; qualitative disclosures show continued dependence on JAKAFI amid pipeline progress and a new Vega Therapeutics acquisition.
Last 4 quarters: 3 beats, 1 miss
Reported EPS of $3.09 versus the $2.14 analyst consensus — a +44.1% beat for Jun 2026.
In May 2026, the FDA approved JAKAFI XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and steroid-refractory acute/chronic GVHD, broadening the hematology franchise's lead product line beyond the original JAKAFI formulation.
Source: 10-Q Item 2 MD&A
In January 2026, Incyte announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide plus R-CHOP as first-line therapy for DLBCL, meeting both the primary endpoint (progression-free survival) and key secondary endpoint (event-free survival); global regulatory submissions were accepted in Q2 2026 with potential U.S. approval/launch anticipated in Q1 2027.
Source: 10-Q Item 2 MD&A
Following FDA Breakthrough Therapy designation granted in December 2025 for essential thrombocythemia (ET), a Phase 3 registrational study of INCA033989 in Type 1 and non-Type 1 mutCALR-positive ET patients was initiated in mid-2026, with a Phase 3 trial in myelofibrosis anticipated in the second half of 2026.
Source: 10-Q Item 2 MD&A
In July 2026, Incyte completed the acquisition of Vega Therapeutics, adding latarcibart, a Phase 3 monoclonal antibody for von Willebrand disease with Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations; Phase 1/2 data presented at the 2026 ISTH Congress showed an 81% median reduction in annualized bleeding rate.
Source: 10-Q Item 2 MD&A
Management notes that patents covering ruxolitinib composition of matter and salt use expire in mid and late 2028 respectively, after which JAKAFI product sales are expected to begin declining, underscoring the urgency of pipeline diversification efforts described in the MD&A.
Source: 10-Q Item 2 MD&A
Incyte states that JAKAFI product sales are expected to continue contributing a significant percentage of total revenues over the next several years, but sales are expected to begin declining upon patent exclusivity expiration in 2028. Any inability to maintain JAKAFI revenues could materially harm the business and force delays in other drug discovery and commercialization initiatives.
Source: 10-Q Item 1A
The filing describes risks that government health authorities, private insurers, and PBMs could limit coverage, impose formulary exclusions, step edits, or require incremental rebates/discounts, which could adversely affect product pricing and sales. Increasing 340B program participation and international reference pricing add further pressure on realized prices.
Source: 10-Q Item 1A
Incyte depends on a limited number of specialty pharmacies and wholesalers for a significant portion of revenues from JAKAFI and other products; the loss of, or significant reduction in sales to, any one of these partners could materially and adversely affect operations and financial condition.
Source: 10-Q Item 1A
The FDA's 2021 class boxed warning update for JAK inhibitors (including JAKAFI and OPZELURA) regarding cardiovascular events, thrombosis, and secondary malignancies could negatively affect future sales; failure to comply with FDA and healthcare fraud/abuse laws could result in fines, penalties, or loss of marketing approval.
Source: 10-Q Item 1A
Incyte competes against companies with substantially greater financial, operational, and human resources, including large global pharmaceutical firms and smaller biotech competitors developing potentially safer, more effective, or cheaper alternatives, which could render Incyte's products less competitive.
Source: 10-Q Item 1A
This analysis does not extract a guidance section. Companies issue revenue and EPS outlook in the 8-K press release and on the earnings call rather than in the 10-Q itself — though the filing's management discussion can contain forward-looking statements, which appear in the highlights above where they were material.
Incyte (INCY) is next expected to report on , when the following quarter's results and any updated outlook will be available.
See the INCY earnings preview — expected date, analyst estimates and what to watch →
This filing did not include XBRL income statement data (revenue, net income, or EPS), so a comparison to analyst estimates cannot be made from the information provided. Investors should consult Incyte's press release or full financial statements for specific reported figures.
The key qualitative takeaways include FDA approval of JAKAFI XR extended-release tablets in May 2026, positive Phase 3 frontMIND results for tafasitamab in DLBCL, and the completed acquisition of Vega Therapeutics adding latarcibart for von Willebrand disease. No quantitative financial metrics were available in the provided data for this period.
Incyte's principal disclosed risks include heavy dependence on JAKAFI/JAKAVI revenue (with patent exclusivity expiring in 2028), reimbursement and pricing pressure from payors and PBMs, and concentration risk from relying on a limited number of specialty pharmacies and wholesalers for distribution.
Incyte reported that a Phase 3 registrational trial of INCA033989 in mutCALR-positive essential thrombocythemia began in mid-2026, with a myelofibrosis Phase 3 trial anticipated in the second half of 2026, and global regulatory submissions for tafasitamab plus R-CHOP in DLBCL were accepted in Q2 2026 with potential U.S. approval in Q1 2027.
This particular filing did not provide XBRL balance sheet, income statement, or cash flow data, so metrics like liquidity, profitability, and leverage cannot be assessed from the information given. Investors should refer to Incyte's full financial statements or investor relations materials for detailed financial health indicators.
Incyte (INCY) is next expected to report earnings on Oct 26, 2026. The date comes from the analyst earnings calendar and can shift until the company confirms it.
Expected release date, analyst estimates & what to watch
Incyte Corporation delivered a strong Q1 FY2026, with revenue surging 20.9% YoY to $1.27B and net income nearly doubling to $303.3M, driven by robust product sales and disciplined cost management.
Incyte Corporation delivered a transformational FY2025, with revenue surging 21.2% to $5.14B and net income skyrocketing to $1.29B (from $32.6M), driven by a dramatic reduction in R&D spending and strong commercial momentum, resulting in a 29.5% operating margin.
Other companies in Biotechnology